Top 2 Health Care Stocks That May Plunge In August
Top 2 Health Care Stocks That May Plunge In August
As of Aug 26, 2024, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
截至2024年8月26日，医疗保健板块中的两只股票对于那些将动量视为其交易决策关键因素的投资者可能会发出真正的警告。
The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro.
RSI是一种动量指标，它将股票在股价上升的日子里的强度与在股价下跌的日子里的强度进行比较。与股票价格的走势相比，它可以让交易员更好地了解股票在短期内的表现。当RSI高于70时，资产通常被认为是超买的，据Benzinga Pro称。
Here's the latest list of major overbought players in this sector.
以下是行业中超买的主要股票列表。
Beigene Ltd (NASDAQ:BGNE)
百济神州有限公司（NASDAQ：BGNE）
- On Aug. 7, BeiGene posted better-than-expected second-quarter financial results. "This was a tremendous second quarter and an inflection point as BeiGene achieved positive non-GAAP operating income with rapidly increasing global revenues and continued financial discipline. Having now reached this milestone, we will further build on our differentiated, strategic capabilities as a leading, global oncology innovator," said John V. Oyler, Co-Founder, Chairman and CEO of BeiGene. The company's stock gained around 19% over the past month and has a 52-week high of $219.64.
- RSI Value: 72.54
- BGNE Price Action: Shares of Beigene fell 0.9% to close at $193.82 on Friday.
- 2024年8月7日，百济神州发布了超预期的第二季度财务业绩。“这是一个巨大的第二季度，也是百济神州在不断增长的全球收入和持续财务纪律方面实现了正面非通用会计原则营业收入的转折点。达到这个里程碑后，我们将进一步发展我们作为领先的全球肿瘤创新者的差异化战略能力，”百济神州联合创始人、董事长兼首席执行官John V. Oyler表示。该公司的股价在过去一个月内上涨了约19%，并且达到了52周的最高点$219.64。
- RSI值：72.54
- 百济神州的股价行情：Beigene股票于周五下跌了0.9%，收盘价为$193.82。
Halozyme Therapeutics, Inc. (NASDAQ:HALO)
奥洛兹美医疗公司（NASDAQ：HALO）
- On Aug. 6, Halozyme Therapeutics reported better-than-expected second-quarter financial results. "Our strong financial results reflect another quarter of double-digit royalty revenue, EBITDA and earnings growth. We remain on track to deliver on our financial guidance for the full year that was recently raised following the issuance and validation of a new EU patent covering the ENHANZE rHuPH20 product. In the quarter, we also expanded ENHANZE into neurology treatment with Roche's EU and UK approval of Ocrevus SC, while also extending our reach into auto-immune diseases with argenx's FDA approval for VYVGART Hytrulo for the treatment of CIDP," said Dr. Helen Torley, president and chief executive officer of Halozyme. The company's stock gained around 12% over the past month and has a 52-week high of $62.86.
- RSI Value: 76.12
- HALO Price Action: Shares of Halozyme Therapeutics gained 1.8% to close at $62.72 on Friday.
- 8月6日，奥洛兹美医疗发布了超出预期的第二季度财务业绩报告。我们强劲的财务业绩体现了双位数的版税收入、EBITDA和盈利增长。我们将按照最近因发布和验证涵盖ENHANZE rHuPH20产品的新欧盟专利而提高的全年财务指引继续推进。在这个季度，我们还通过罗氏公司在欧盟和英国批准的Ocrevus SC扩展了ENHANZE，同时还通过argenx公司获得了VYVGARt Hytrulo用于CIDP治疗的FDA批准，进入了自身免疫性疾病领域。奥洛兹美医疗总裁兼首席执行官Helen Torley博士表示:"我们公司股价在过去一个月上涨了约12%，并且股价创下了62.86美元的52周高点。"
- RSI数值：76.12
- HALO价格走势：奥洛兹美医疗股价周五上涨1.8%，收于62.72美元。
Read More:
阅读更多：
- Jim Cramer Praises L3Harris Technologies, Says Intel Is 'Getting Whacked' By AMD: 'I Much Prefer...'
- 吉姆·克雷默赞扬L3Harris Technologies，并表示英特尔（Intel）正受到AMD的打击：'我更喜欢……'